These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1135 related articles for article (PubMed ID: 7805002)

  • 41. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
    Becker JC; Pancook JD; Gillies SD; Mendelsohn J; Reisfeld RA
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2702-7. PubMed ID: 8610104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Melanoma].
    Saida T
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1386-91. PubMed ID: 17033225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Successful treatment of cutaneous metastatic melanoma with high-dose intralesional interleukin-2 treatment combined with cryosurgery.
    Martinez-Lopez A; Almazan-Fernandez FM; Perez-Lopez I; Aguayo-Carreras P; Salvador-Rodriguez L; Cuenca-Barrales C; Arias-Santiago S
    Dermatol Ther; 2018 Jul; 31(4):e12612. PubMed ID: 29766618
    [No Abstract]   [Full Text] [Related]  

  • 44. Emerging therapies for melanoma.
    Katipamula R; Markovic SN
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):553-60. PubMed ID: 18402522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Drug clinics. How I treat cutaneous melanoma].
    Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 1998 Jan; 53(1):4-6. PubMed ID: 9555173
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The adjuvant treatment of malignant melanoma.
    Reintgen D; Kirkwood J
    J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Next generation of immunotherapy for melanoma.
    Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
    J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adjuvant application of interferons.
    el Kassas H; Kirkwood JM
    Semin Oncol; 1996 Dec; 23(6):737-43. PubMed ID: 8970596
    [No Abstract]   [Full Text] [Related]  

  • 51. Do we have to pay more attention to vitiligo patients? Peculiar histopathological features of primary cutaneous melanoma preceded by vitiligo.
    Onsun N; Büyükbabani N; Ummetoğlu O; Cebeci F
    J Dermatol; 2009 Nov; 36(11):612-5. PubMed ID: 19878396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic factors in 1,521 melanoma patients with distant metastases.
    Barth A; Wanek LA; Morton DL
    J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years' Experience: A Meta-Analysis of 3312 Patients.
    Bright R; Coventry BJ; Eardley-Harris N; Briggs N
    J Immunother; 2017 Jan; 40(1):21-30. PubMed ID: 27875387
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
    Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
    G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematic review of medical treatment in melanoma: current status and future prospects.
    Garbe C; Eigentler TK; Keilholz U; Hauschild A; Kirkwood JM
    Oncologist; 2011; 16(1):5-24. PubMed ID: 21212434
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metastatic malignant melanoma.
    Markovic SN; Erickson LA; Flotte TJ; Kottschade LA; McWilliams RR; Jakub JW; Farley DR; Tran NV; Schild SE; Olivier KR; Vuk-Pavlovic S; Sekulic A; Weenig RH; Pulido JS; Quevedo JF; Vile RG; Wiseman GA; Stoian I; Pittelkow MR;
    G Ital Dermatol Venereol; 2009 Feb; 144(1):1-26. PubMed ID: 19218908
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metastatic melanoma - a review of current and future treatment options.
    Maverakis E; Cornelius LA; Bowen GM; Phan T; Patel FB; Fitzmaurice S; He Y; Burrall B; Duong C; Kloxin AM; Sultani H; Wilken R; Martinez SR; Patel F
    Acta Derm Venereol; 2015 May; 95(5):516-24. PubMed ID: 25520039
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Current aspects in the treatment of malignant melanoma].
    Barth A; Cerny T
    Schweiz Med Wochenschr; 1994 Sep; 124(36):1592-603. PubMed ID: 7939527
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV disease.
    Fox MC; Lao CD; Schwartz JL; Frohm ML; Bichakjian CK; Johnson TM
    J Am Acad Dermatol; 2013 Jan; 68(1):13.e1-13; quiz 26-8. PubMed ID: 23244384
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cutaneous head and neck melanoma: the old and the new.
    Rigual NR; Popat SR; Jayaprakash V; Jaggernauth W; Wong M
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):403-12. PubMed ID: 18366288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.